Abstract. MicroRNAs (miRNAs) have been implicated in the maintenance of the cancer stem cell (CSC) phenotype via their ability to affect expression of genes and proteins that regulate cell proliferation and/or cell death. Thus, identification of CSC-related miRNAs would provide information for a better understanding of CSCs. Here, we compared the miRNA profiles of CD133 + and CD133 -primary hepatocellular carcinoma (HCC) subpopulations and found upregulation of 5 miRNAs in CD133 -subpopulations, including hsa-miR-150, which may be involved in maintenance of the CD133 + liver CSC phenotype. We also show that miR-150 interacts with the 3'UTR of c-Myb mRNA and overexpression of miR-150 downregulates c-Myb protein levels. Furthermore, overexpression of miR-150 lead to a significant reduction of CD133 + cells, accompanied by significant inhibition of cell growth and tumorsphere formation. In addition, overexpression of miR-150 induces cell cycle arrest and apoptosis in CD133 + cells. Consistent with the outcome of cell cycle arrest and cell apoptosis, Western blotting results demonstrate that the cell cycle regulator cyclin D1 and cell survival regulator Bcl-2 are decreased in cells transfected with miR-150. Collectively, our findings demonstrate for the first time that miR-150 may be involved in liver CSC self-renewal, potentially via modulation of the downstream target c-Myb.
Introduction
The cancer stem cells (CSCs) hypothesis suggests that only a small subset of cells possesses the stem property of self-renewal, clonogenicity and tumorigenicity (1) . There is accumulating evidence for CSCs in many solid tumors, including brain, breast, osteosarcoma, liver, and colon (2) (3) (4) (5) (6) (7) . In this study, we focused on hepatocellular carcinoma (HCC), one of most prevalent cancers in Asia and Africa. Recently, CD133 was used as a marker to isolate liver CSCs (8, 9) . microRNAs (miRNAs) are a novel class of small noncoding RNAs that negatively regulate gene expression (10) (11) (12) (13) (14) . Emerging evidence suggests that miRNAs may play important roles in cancer (15) (16) (17) . miRNAs can function as both oncogenes and tumor suppressors in their effect on tumor growth (18, 19) . Recent data demonstrate that miRNAs are important factors in stem cell biology and in the determination of cell fate (20) (21) (22) whereas the knowledge on miRNAs expression in liver CSCs is still preliminary. CD133 + HCC subpopulations with stem cell properties have been reported whereas the CD133 -subpopulations include differentiated tumor cells. We hypothesize that up-regulation of miRNAs in CD133 -cells indicates that they drive CD133 + cells to differentiate and lose their stem cell properties. Hence, overexpression of these miRNAs in CD133 + cells may inhibit cell self-renewal. Therefore, we compared the miRNA profiles of CSCs with that of the non-stem cell population in HCC. Interestingly, several miRNAs have been found up-regulated in the CD133 -subpopulations. Among these miRNAs, miR-150, a gene is on chromosome 19q13, was noted during the experiments. Previous studies reported potential growthand differentiation-dependent regulatory roles for miR-150 in immune cells (23) . The report from Cheng et al, indicated that ectopic expression of miR-150 induces cell cycle arrest, which is consistent with the ability of miR-150 to down-regulate a program of genes promoting cell cycle progression (24) . Taken together, these studies suggest that miR-150 may have a key role in regulating the balance among cell differentiation and survival.
However, little is known about the functions of miR-150 in liver cancer stem cells. In the present study, we examined the effects of functional overexpression of miR-150 by miR-150 lentiviral vector on CD133 + SMMC-7721 cells. Evaluating the role of miR-150 in regulation of cell growth and apoptosis, and its potential link to liver cancer stem cells may provide a new avenues for therapeutic interventions for targeting liver CSCs.
microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb
Materials and methods HCC cell lines, HCC samples and cell culture. Human HCC cell lines (SMMC-7721, Huh-7, and Hep3B) were obtained from the Cell Bank of Institute of Biochemistry and Cell Biology, China Academy of Sciences (Shanghai, China). Tumor samples were obtained with informed consent from 5 patients who underwent hepatocellular carcinoma in the Department of Surgery, the First Affilicated Hospital, Chongqing Medical University (Chongqing, China). Tumor processing and cell cultures were done as described (9) . All human sample collection procedures were approved by the China Ethics Review Committee. The characteristics of HCC patents included in this study are described in Table I .
Magnetic sorting and culture of CD133
+ SMMC-7721 cells. For magnetic cell sorting cells were labeled with CD133/1 magnetic microbeads and sorted using the CD133 Cell Isolation Kit (Miltenyi Biotec), according to the manufacturer's protocol as described (8) . Magnetic separation was performed to obtain >95% pure CD133 + SMMC-7721 cells and >95% pure CD133 -SMMC-7721 cells. The purity of sorted cells was evaluated by FACS with the FACSCalibur apparatus (Becton-Dickinson, USA) and Western blotting. After sorting, the CD133 + cells were cultured in serumfree stem cell medium containing DMEM/F12, 20 ng/ml basic fibroblast growth factor (bFGF, Miltenyi Biotec), 20 ng/ml epidermal growth factor (EGF, Miltenyi Biotec), 20 ng/ml leukemia inhibitory factor (LIF, Miltenyi Biotec), 100 IU/ml penicillin G and 100 µg/ml streptomycin (Sigma, USA).
Expression profiling of miRNAs. For miRNA profiles analysis, total RNA was isolated from the HCC CD133 + fractions and CD133 -fractions using TRIzol (Invitrogen) and RNeasy mini kit (Qiagen), according to the instructions. Following RNA measurement on the Nanodrop instrument, the samples were labeled using the miRCURY™ Hy3™/Hy5™ Power labeling kit and hybridized on the miRCURY™ locked nucleic acid (LNA) microarray platform (Exipon, Denmark). The samples were hybridized on a hybridization station. Arrays were scanned using the Axon GenePix 4000B microarray scanner. Differentially expressed miRNAs were identified using a filter based on 1.5-fold changes combined with t-test (P<0.01) for CD133 + versus CD133 -comparisons.
Transfection of CD133
+ SMMC-7721 cells. The HIV lentiviral system expression miR-150 and miR-control were commercially synthesized (Shanghai Sunbio Medical Biotechnology Co. Ltd, China). Transfection was performed with polybrene (Sigma, USA) according to the instructions. Briefly, CD133
+ SMMC-7721 cells were seeded in six-well plates and grown overnight. Then the cells were transfected at a multiplicity of infection (MOI) of 50 with the miR-150 or miR-control, and 24 h later the medium was changed to fresh culture medium.
Flow cytometry analysis. The CD133 expression studies were carried out according to the instructions. Briefly, the fresh sorted cells were blocked in FcR Blocking Reagent Kit and labeled with FITC-conjugated anti-human CD133/2 (Miltenyi Biotec). Isotype-matched mouse antibodies served as controls. The flow cytometry analysis of cell cycle and apoptosis were carried out using a FACSCalibur flow cytometer (BD Biosciences, USA). Annexin V and propidium iodide (PI) dual staining was used to visualize apoptotic cells.
Colony formation and tumorsphere formation assays. For colony formation assays, 1,000 CD133 + or CD133 -SMMC-7721 cells were seeded in 6-cm culture plates (Cornig, USA). After 3 weeks, the colonies were stained with Giemsa solution. Tumorsphere formation assays were performed essentially as previously described (25) . Briefly, single cell suspensions of 10,000 CD133 + or CD133 -SMMC-7721 cells were seeded in ultra-low 6-well plates (Cornnig, USA). Tumorspheres were observed after 7 days under inverted microscope (Olympus, Tokyo, Japan).
Xenograft tumorigenicity assay. Six-to eight-week-old NOD/ SCID mice were purchased from Chongqing University of Medical Sciences (Chongqing Province, China). The protocols were approved by the institutional Animal Care and Use Committee. All mice were randomly divided into groups (5 mice/ group) and maintained under standard conditions according to the institutional guidelines. For subcutaneous inoculation, various numbers of CD133 + or CD133 -cells ranging from 100 to 10,000 cells were suspended in DMEM/F12 and Matrigel (Invitrogen) mixture (1:1), and subcutaneous injection was performed. All animals were sacrificed with an overdose of ketanest and xylazine. The incidence of subcutaneous tumors was recorded. To examine the expression of CD133 in the transplanted cells, the grafts were treated with collagenase, and the isolated cells were analyzed by FACS. The subcutaneous tumors were formalinfixed and paraffin-embedded for histological analysis.
RNA extraction, real-time PCR and semi-quantitative RT-PCR.
Total RNA was extracted from cells using TRIzol (Invitrogen, USA). Revere transcription was performed on 10 ng of total RNA, cDNA was used in PCR reactions of 40 cycles (94˚C, 5 min, 94˚C 30 sec, 58˚C, 30 sec, 72˚C, 40 sec). miRNA levels were determined by real-time PCR. Amplification and detection of specific products were performed with the Rotor-Gene 3000 real-time PCR system (Corbett Research). All the primers used for real-time PCR are listed in Table II β-actin forward 5'-AGCGAGCATCCCCCAAAGTT-3', reverse 5'-GGGCACGAAGGCTCATCATT -3'. β-actin was used as an internal control. PCR products were analyzed by 2.5% agarose gels.
Cell proliferation assays. Cell proliferation was examined on days 0, 1, 2, 3, 4 and 5 after inoculation by means of a cell proliferation assay using Cell Counting Kit-8 (CCK-8) (Beyotime Ins. Biotec, China) according to the manufacturer's instructions. The optical density was measured using the microplate reader at a wavelength of 450 nm.
Luciferase reporter assay. The 3'UTR fragment (nt904 to nt910 and nt968 to nt974) of human c-Myb mRNA contained 2 putative target sites for miR-150. The fragment was cloned into the firefly luciferase reporter vector pMIR-Report (Ambion). Mutation of the c-Myb 3'UTR at the miR-150 binding site was performed using the Quick change-mutagenesis kit (Stratagene, Heidelberg, Germany). For reporter assays, the cells were plated in 24-well plates, and co-transfected with wild-type or mutant reporter and miR-150-expression plasmid using Lipofectamine 2000 (Invitrogen). Cells were harvested 48 h after transfection and lysed in lysis buffer. Luciferase activity was measured using the dual luciferase reporter assay system (Promega).
Western blot analysis. Cell lysis, sample preparation, SDS-PAGE separation and electro-transferring to nitrocellulose membrane were performed with standard methods. The primary antibodies used for analysis included rabbit anti-cMyb polyclonal Ab (1:1000), rabbit anti-cyclin D1 polyclonal Ab (1:1000), mouse anti-Bcl-2 mAb (1:1000), mouse anti-CD133 mAb (1:1000), and mouse anti-α-tubulin mAb (1:1000), all from Santa Cruz Biotechnology (Santa Cruz, USA). The signal was visualized with ECL chemiluminescent substrates on X-ray film (Kodak, USA). The expression levels were quantified as the band density on X-film using Image Quant software, calculated as the ratio to α-tubulin expressed in the same sample.
Statistical analysis. All values are presented as means ± standard deviation (SD). Significant differences were determined using SPSS 11.5 software. Student's t-test analysis was used to determine the statistical difference. P<0.05 was considered significant.
Results

Isolation of CD133 + and CD133
-fractions from primary HCC sample. We used the antibody coated magnetic beads (Miltenyi Biotec) to sorted cancer stem cells (CD133 + ) and non-stem (CD133 -) cells from primary HCC samples derived from five patients. The CD133 + subpopulations in the freshly dissociated primary HCC cells ranging from 0.20 to 9.13% were analyzed by flow cytometry (Fig. 1A) . After sorting, the content of CD133 + subpopulation was enriched up to 99.73% (Fig. 1B) and each fraction formed tumorspheres within 24-72 h, whereas the CD133 -cells did not exhibit tumorsphere formation (Fig. 1C) .
Microarray analysis of miRNA expression profiling. To examine the differential expression profile of miRNAs in CD133 + and CD133 -HCC fractions, miRNA microarray analysis was performed using the miRCURY LNA Array (v.14.0) from Exiqon. Heat map and hierachical clustering analysis are shown in Fig. 2A . The results show that cell samples were clustered according to expression profile of 1.5-fold differentially expressed miRNAs between CD133 + and CD133 -of primary HCC fractions. Interestingly, several miRNAs were up-regulated in the CD133 -HCC fractions (Table II) . These include hsa-miR-150, hsa-miR-152, hsa-miR-888, hsa-miR-519e, hsa-miR-532-5p.
To further confirm results from microarray and to examine tissue distribution of miRNA expression, 5 miRNAs from the hsa-miR-152, hsa-miR-888, hsa-miR-519e, and hsa-miR-532-5p were higher in CD133 -HCC fractions (Fig. 2B) .
Sorting of CD133
+ cells from HCC cell line SMMC-7721. We examined a series of human HCC cell lines (SMMC-7721, Huh-7, and Hep3B) for miR-150 expression. SMMC-7721 cells have very low expression level of miR-150, but high levels of the miR-150 target gene c-Myb (not shown). Based on these data and our observation that they are reproducible from tumorspheres, we chose the SMMC-7721 cells for the current study. To define the frequency of CD133 + cells in SMMC-7721 cell line, we evaluated the CD133 expression by flow cytometry. As shown, we found that CD133 + cells were only a small fraction of in SMMC-7721 (0.15-0.54%). We successfully enriched CD133 + and CD133
-populations from SMMC-7721 cells by MACS, with >98% purity in CD133 + cells after sorting (Fig. 3A) . Differential expression level of CD133 protein in the sorted populations was confirmed by Western blotting. Notably, we found the expression of CD133 protein was significantly increased in the CD133 + cells (Fig. 3B) . In addition, we observed a marked change in cellular morphology between CD133 + and CD133 -SMMC-7721 cells. The CD133 -SMMC-7721 cells grew as evenly distributed adherent monolayers, whereas CD133 + SMMC-7721 cells grew in aggregate clusters of cells (Fig. 3C) and 98.88% CD133 -cells (Fig. 3D ). This proportion was consistent with the initial composition of SMMC-7721 cells.
CD133
+ HCC cells show higher proliferation, colony formation, and tumorsphere formation ability. To determine whether CD133 + cells represent the CSCs phenotype, we carried out the cell proliferation, colony formation and spheroid formation ability assays. As shown in Fig. 4A and B, CD133 + cells possessed significantly higher proliferation than CD133 -cells. The proliferation rate of CD133 + cells was significantly higher than CD133
-cells on the fifth day. In the colony formation assay, we found CD133 + cells possessed higher colony formation efficiency than CD133 -cells. As shown in Fig. 4C and D, CD133 + cells formed larger and greater number of colonies than CD133 -cells. We further pursued these cells for their ability to form tumorspheres as an indicator of stem cell self-renewal. We found that the CD133 + cells formed tumorspheres within 48 h, whereas the CD133 -cells did not form tumorspheres (Fig. 4E) . Furthermore, CD133
+ cells formed tumorspheres efficiently, reaching ~200 µm in diameter after 7 days of culture (Fig. 4F) .
Tumor formation and self-renewal of CD133
+ cells. To determine whether CD133
+ cells were capable of tumor initiation, we compared the abilities of CD133 + versus CD133 -cells to initiate tumor formation in NOD/SCID mice. An apparent difference in tumorigenicity was observed between CD133 + and CD133 -cells (Table IV) . As few as 1,000 CD133 + cells were sufficient to initiate tumors in 2 of 5 subcutaneous inoculations in NOD/SCID mice 6 weeks after inoculation. Furthermore, 10,000 CD133 + cells produced tumors in 5 of 5 inoculations in NOD/SCID mice, whereas no tumors were found in inocula- tion of 10,000 CD133 -cells (Fig. 5A) . Hematoxylin-eosin (H&E) staining analysis of xenograft tumors showed a highly cellular mass below the CD133 + cell injection site (Fig. 5B ). To determine whether CD133 + cells self-renew and generate CD133 -cells in vivo, flow cytometry analysis was performed to characterize the CD133 + engraftment (Fig. 5C ). FACS analysis revealed that the tumor cells consisted of 2.16% CD133 + cells and 97.84% CD133 -cells.
The c-Myb is a direct target of miR-150.
To gain insights into the biological functions of miR-150, we performed analysis of potential targets of miR-150 using two common prediction algorithms, TargetSCAN (http://www.targetscan.org/) and PicTar (http://pictar.mdc-berlin.de/) focusing on genes known to regulate cell proliferation, differentiation and survival. c-Myb was among the top target genes predicted for miR-150.
To determine whether c-Myb is a direct target of miR-150, we integrated a fragment of the c-Myb-3'UTR containing the target sequence, or a fragment of the c-Myb-3'UTR-mut, into a luciferase reporter vector (Fig. 6A) . Cotransfection with c-Myb-3'UTR and miR-150 caused a 36% decrease in the luciferase activity compared with the negative control (Fig. 6B) . These + cells significantly decreased c-Myb protein expression, while the miR-control or blank control had no effect on expression of c-Myb protein (Fig. 6C) . RT-PCR analysis demonstrated that miR-150 has little if any effect on c-Myb mRNA levels (Fig. 6D) . (Fig. 7B) . This miR-150-induced reduction of the CD133 + cells was accompanied by reduced tumorsphere formation and smaller size of the tumorspheres (Fig. 7C) .
Overexpression of miR-150 leads to cell cycle arrest and promotes apoptosis in CD133
+ cells. Overexpression of miR-150 inhibits CD133
+ cells proliferation and leads to partial dispersion of spheroids. Thus, we looked for potential cell cycle and apoptosis alterations in CD133 + cells transfected with miR-150. FACS showed that overexpression of miR-150 induced a 42% decrease in S-phase fractions, and an increase in G 1 of 33%, as compared to the cells transfected with miR-control ( Fig. 8A  and B) . Furthermore, we also measured the apoptotic cells by flow cytometry analysis. It was observed that up to 25.21±9.26% of CD133 + cells became apoptotic on 72 h after transfected with miR-150, whereas the apoptosis was 6.39±1.02% in the blank control group (Fig. 8C and D) . We additionally examined expression of several molecules involved in cell cycle and cell survival regulation. As illustrated in Fig. 7E , overexpression of miR-150 significantly decreased the expression of cyclin D1 and Bcl-2 protein levels. 
Discussion
This study is based on the cancer stem cells (CSCs) hypothesis that tumors contain only a small subset of cells which maintain the proliferation, self-renewal and differentiation of tumor. Therefore, according to CSCs model (26, 27) , targeting the minor population of CSCs may be a effective and curative therapeutic strategy for eradicating cancer. Here, we sorted CD133 + cells from SMMC-7721 cells, which demonstrated many CSCs-like properties. We used CD133 + liver CSCs as a model for testing the differences in expression profiles of miRNAs since recent studies suggest a role for miRNAs in CSCs (28) (29) (30) (31) (32) .
Our analysis of differential expression of miRNAs in CD133 + and CD133 -of primary HCC tumor fractions revealed overexpression of several miRNAs in the CD133 -fractions. Among the differentially expressed miRNAs, we focused on the hsa-miR-150, as miR-150 was recently reported selectively expressed in hematopoietic progenitors and certain solid tumors (34) (35) (36) (37) . However, the biological functions and mechanisms of miRNA-150 in liver CSCs have not been elucidated. It has become clear that the physiological function of miRNA is based on the regulation of only few critical target gene expressions in cellular context. In order to understand the impact and the molecular mechanisms underlying its function, we search for target genes that may be regulated by miRNA-150. We explored the molecular mechanism underlying its function that c-Myb was a direct target of miR-150. c-Myb is a transcription factor that is involved in cell proliferation, differentiation, and survival (38) (39) (40) .
In the present study, we overexpressed miR-150 in CD133 + cells and observed the effect on cell proliferation and tumorsphere formation. Surprisingly, overexpression of miR-150 significantly inhibited cell proliferation and led to partial dispersion of tumorspheres in CD133 + HCC cells. We next determined whether the effect of miR-150 on cell proliferation was related to cell cycle arrest and cell apoptosis. Overexpression of miR-150 increased the apoptosis and G 1 arrest in the cell cycle of CD133 + HCC cells. This study demonstrated that overexpression of miR-150 in CD133
+ HCC cells leads to alterations of several key proteins involved with cell cycle and cell survival, including cyclin D1 and Bcl-2. These changes can be attributed to the down-regulation of c-Myb in response to miR-150 overexpression. The functional effects of c-Myb are modulated by transcription factors/cell cycle protein, including c-Myc, cyclinD1, Bcl-2 and Bcl-X (41-46).
In conclusion, our study demonstrated that miR-150 may be involved in CD133 + liver CSCs self-renewal, at least in part, through the direct negative regulation of the downstream target c-Myb. Overexpression of miR-150 led to increased percentage of cells in G 1 phase and a substantial increase in cell apoptosis in CD133 + HCC cells. We observed down-regulation of cell cycle regulator cyclin D1 and cell survival regulator Bcl-2, which is generally consistent with the outcome of cell cycle arrest and cell apoptosis. Our study suggests that miR-150 may play a critical role in CD133 + liver CSC self-renewal and cell fate determination, and its potential function in liver CSCs may provide a novel therapeutic approach for HCC.
